Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer was focused on recently. A caller asked if the ...
At the upcoming Lived! 360 Orlando 2025 conference, Tim Purdum, Engineering Manager and Senior Software Engineer at dymaptic, ...
Recursion Pharmaceuticals (RXRX) saw a sharp uptick in trading as investors looked ahead to the CEO's upcoming presentation at a major AI conference. The focus is on how the company’s AI strategy and ...
Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.3 billion market cap biotech company currently trading at $5.31, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...
In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback